Simeglutide is used primarily as a hypoglycemic drug and is susceptible to elevated blood glucose when the drug is abruptly discontinued. Simeglutide is a glucagon-like peptide-1 analog that acts as a glucagon-like peptide-1 receptor agonist, selectively binding to and activating the receptor, stimulating insulin secretion and decreasing glucagon secretion, thereby lowering blood glucose. The mechanism by which simepaglutide lowers blood glucose also involves a slight delay in early postprandial gastric emptying. Sudden discontinuation of simepaglutide when used as a hypoglycemic agent for blood glucose control may result in a sudden decrease in insulin secretion as well as an increase in glucagon secretion, leading to a rebound in blood glucose. Therefore, it is recommended to take the medication as prescribed by the doctor. Adverse effects of simethicone include hypoglycemia, gastrointestinal reactions such as nausea, vomiting and diarrhea, etc. It is contraindicated for those who are hypersensitive to the active ingredients of the drug or any of its excipients, and for women during pregnancy. The use of simepaglutide should be carried out under the guidance of a doctor, do not blindly use the drug, in order to avoid adverse consequences.